Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CPS1 | P31327 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311973 | 0.84 | KDM4E (0.67) | KDM4EMAPTMAPK1MAOBMAOA | |
| SCHEMBL14034583 | 0.84 | KDM4E (0.56) | KDM4EMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL1555099 | 0.82 | CPS1 (0.61) | MAPK1LMNAALDH1A1ALOX15CYP3A4 | |
| SCHEMBL7326050 | 0.81 | KDM4E (0.53) | KDM4EMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL14744132 | 0.81 | KDM4E (0.72) | KDM4EMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL31621879 | 0.80 | LMNA (0.52) | KDM4EMAPTMAPK1MAOBMAOA | |
| SCHEMBL823757 | 0.80 | LMNA (0.52) | KDM4EMAPTMAPK1MAOBMAOA | |
| SCHEMBL23668248 | 0.79 | KDM4E (0.47) | KDM4EMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL3331532 | 0.79 | CHRNA3 (0.49) | KDM4EMAPTMAPK1LMNACYP3A4 | |
| SCHEMBL27580216 | 0.78 | KDM4E (0.58) | KDM4EMAPTMAPK1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
| EP-1375627-B1 | Optically active compound and liquid crystal composition containing the same | MITSUBISHI GAS CHEMICAL CO (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-6699532-B2 | CHIRAL DOPANT HAVING A HELICAL TWISTING POWER (HTP) OF AT LEAST 50 AND HAVING ITS INDUCED HELICAL PITCH DECREASING IN LENGTH WITH AN INCREASE IN TEMPERATURE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20040007691-A1 | OPTICALLY ACTIVE COMPOUND AND LIQUID CRYSTAL COMPOSITION CONTAINING THE COMPOUND | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1375627-A1 | Optically active compound and liquid crystal composition containing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-5595685-A | THIAZOLE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 1997-01-21 | — | — | US | disclosed |
| EP-0439170-B1 | Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus | CANON KK (JP) | 1995-04-19 | — | — | EP | disclosed |
| EP-0439170-A2 | Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus | CANON KABUSHIKI KAISHA (JP) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | KDM4E 3504/4885MAPT 2914/4885MAPK1 1630/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | KDM4E 3504/4885MAPT 2914/4885MAPK1 1630/4885 |
| US-20040007691-A1 | OPTICALLY ACTIVE COMPOUND AND LIQUID CRYSTAL COMPOSITION CONTAINING THE COMPOUND | TOP1, ROCK1, SFRP1 | KDM4E 4611/4885MAPT 30/4885MAPK1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.